Salvage treatment for patient with multiple myeloma refractory to alkylating agents.
Sixteen patients with multiple myeloma refractory to alkylating agents were treated with vincristine 0.25 mg/m2 i.v. on days 1 to 4 and prednisone 1 gm/m2 on days 1 and 3. Chemotherapy was repeated every 2 weeks. Of 15 evaluable patients, five achieved a partial response and four stable disease. Three patients with partial response and three with stable disease relapsed at 6, 7, and 16 and at 5, 9, and 10 months, respectively. The median survival for all patients was 10 1/2 months and it ranged from 1 to 21 + months. The median survival in responders was not reached at 13 months. Onset of antitumor effect was observed within the first 2 weeks. Symptomatic relief of bone pain was noted within 48 hours in responders and nonresponders. Improvement in bone marrow cellularity and decrease in plasma cell infiltration was documented in more than one-half of the responders. Tolerance to the treatment was good. No hematologic or other significant toxicity was observed.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009194:Myeloma Proteins / Q000032:analysis; D011241:Prednisone / Q000008:administration & dosage; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D001798:Blood Proteins; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D009194:Myeloma Proteins; D014750:Vincristine; D011241:Prednisone